Company: TELO
Filing Date: 2025-08-27
Form Type: 8-K
Source: 0001641172-25-025688
Chunk: 0

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-08-27
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item
8.01 Other Events

Telomir
Pharmaceuticals Reports In Vitro Data Supporting the Potential of Telomir-1 as a First-in-Class Epigenetic Therapy Influencing DNA Methylation
Pathways in Cancer, Aging, and Age-Related Diseases

In
vitro findings reveal Telomir-1’s dual action: targeting DNA methylation switches and cutting into the Wnt “fuel line”
that drives cancer growth.

Telomir
Pharmaceuticals, Inc. (NASDAQ: TELO), a preclinical-stage biotechnology company developing therapies that target the root mechanisms
of cancer, aging, and age-related diseases, today announced new in vitro results that expand understanding of its lead drug candidate,
Telomir-1.

The
studies, conducted by Eurofins Discovery, showed that Telomir-1 potently inhibits UTX (KDM6A), a histone demethylase that interacts closely
with DNA methylation to control which genes are switched on or off. Abnormal UTX activity has been linked to silencing of tumor suppressors
and inappropriate activation of disease-driving genes. This dysregulation is observed in cancer, autoimmune disease, aging, neurodegeneration,
autism spectrum disorder, and metabolic dysfunction. By inhibiting UTX, Telomir-1 demonstrated the potential to reset faulty DNA methylation
patterns and restore more normal gene regulation.

As
previously reported, Telomir-1 also inhibited additional epigenetic enzymes - FBXL10, FBXL11, and JMJD3 - that are implicated
in tumor progression, inflammation, metabolic dysfunction, and neurodevelopmental disorders. In prior prostate cancer studies in vivo,
Telomir-1 reactivated silenced tumor suppressors STAT1 and TMS1 by reversing abnormal DNA methylation, providing functional evidence
of its ability to reset gene programs that are often disabled in cancer.

Importantly,
Telomir-1 showed no activity against GCN5L2 (KAT2A), a broad acetyltransferase enzyme whose inhibition has been associated with widespread
toxicity. This selectivity may provide Telomir-1 with a cleaner safety margin compared to other epigenetic drugs.

The
new in vitro data also showed that Telomir-1 had low-level inhibitory activity against Tankyrases (PARP5A and PARP5B). Tankyrases regulate
the Wnt/β-catenin pathway, one of the body’s